X

Trial Profile

Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Choline alfoscerate (Primary) ; Nimodipine (Primary)
Indications Cognition disorders
Focus Therapeutic Use
Acronyms CONIVAD

Most Recent Events

15 Apr 2021 Primary endpoint (Cognitive decline evaluated by the change of MoCA test score compared with Baseline) has not been met as per Results published in the Drugs and Aging
15 Apr 2021 Results published in the Drugs and Aging
01 Mar 2020 Trial design published in the Aging Clinical and Experimental Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com